-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A7gS6MPFmd7N8RVzjPzWrUEA7NauiB9HmDq/HGrYKwGCqrJGapSxOMpljM0r7Pcj bN7gfKR3lVMPkksaqbNRyQ== 0001193125-06-152518.txt : 20060725 0001193125-06-152518.hdr.sgml : 20060725 20060725143521 ACCESSION NUMBER: 0001193125-06-152518 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20060725 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060725 DATE AS OF CHANGE: 20060725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGEN CORP CENTRAL INDEX KEY: 0000711377 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 382367843 STATE OF INCORPORATION: MI FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17988 FILM NUMBER: 06978766 BUSINESS ADDRESS: STREET 1: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 BUSINESS PHONE: 5173729200 MAIL ADDRESS: STREET 2: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 25, 2006

 


NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

 


 

MICHIGAN   0-17988   38-2367843

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

620 Lesher Place Lansing, Michigan   48912
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code 517-372-9200

 

(Former name or former address, if changed since last report.)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 2.02 Results of Operations and Financial Condition

On July 25, 2006, Neogen Corporation issued a press release announcing results of operations for the fiscal quarter and year ended May 31, 2006. A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits

 

(c)   Exhibits  
  99.1   Press Release dated July 25, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEOGEN CORPORATION
  (Registrant)
Date: July 25, 2006  
 

/s/ Richard R. Current

  Richard R. Current
  Vice President & CFO
EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

FOR IMMEDIATE RELEASE

 

CONTACT:   Richard R. Current
  Chief Financial Officer
  517/372-9200

Neogen reports 34% increase in net income, 15% increase in revenues

LANSING, Mich., July 25, 2006 – Neogen Corporation (Nasdaq: NEOG) today announced a 15% increase in revenues for its 2006 fiscal year, which ended May 31, and a continuation of the company’s outstanding record of profitability. Neogen’s net income increased 35% in its fourth quarter on a prior year quarter-to-quarter comparison, and was up 34% overall for FY 2006.

FY 2006 revenues were $72,433,000, up from $62,756,000 in Neogen’s previous fiscal year. Net income was $7,941,000 in FY 2006, or $0.92 per share, compared to $0.70 in the prior year. Neogen’s fourth quarter was the 53rd consecutive profitable quarter from operations for the company, and the 57th quarter of the past 62 quarters to show revenue increases on a year-to-year comparison.

Neogen’s fourth quarter revenues improved 24% on a year-to-year comparison to $19,815,000. Quarterly net income per share was $0.22 for the final FY 2006 three-month period. In the prior year, Neogen reported fourth quarter revenues of $16,008,000 and net income of $0.17 per share.

“We are proud to report another exceptional year for Neogen, both in terms of revenue growth and operational strength,” said James Herbert, Neogen’s chief executive officer and chairman. “Our almost uninterrupted quarterly growth for the past 15 1/2 years is a tradition our 400 employees work hard to uphold. Not only was this a good financial year, but we also developed new products, established new programs, and made two attractive acquisitions that will help ensure our future growth.”

Neogen’s gross margin in FY 2006 increased to 51.1%, up from 48.8% in the previous fiscal year. Productivity improvements and better utilization of facilities helped drive a 37% improvement in FY 2006 operating income compared to the previous year.

“It is very gratifying to see operating profit reflect our efforts to increase operational efficiencies. Improving our overall gross margins by more than 200 basis points on a year-over-year comparison is a significant improvement,” said Lon Bohannon, who was recently named Neogen’s president and chief operating officer. “I was also very pleased to see that Food Safety diagnostic sales, which includes test kits for pathogens, natural toxins, and food allergens, grow by more than 10% on a same-store basis for both the third and fourth quarters. This represents a significant turnaround from just over one year ago.”

Neogen’s Food Safety Division led the company’s FY 2006 revenue increase with sales up 24% to $34,951,000. While the December 2005 addition of UCB’s dairy antibiotic testing products and the February 2006 addition of Centrus International’s optical microbial detection system contributed significantly to the division’s revenue gain, sales of established products increased 8% for the fiscal year. Due to heightened concern over the presence of aflatoxin in corn in certain areas of the United States, and Neogen’s new extremely simple and accurate strip test format, sales of natural toxin testing products increased 19% in FY 2006 from the previous year.


Neogen continued its unquestioned role as the leader in providing rapid test kits for the most significant food recall concern—food allergens—in the past year, with sales of food allergen tests increasing 39% over FY 2005. Food allergen sales were aided by the introduction of new tests for soy and hazelnut, and an easier test format for milk, but sales of all food allergen products increased significantly in the 12-month period. Sales of this product group continue to be influenced by a U.S. food labeling law that went into effect Jan. 1, 2006, that requires manufacturers to clearly label any known food allergen in their products to protect food allergic consumers.

The company’s December acquisition of UCB’s dairy antibiotic testing business and February acquisition of Centrus International’s microbial test system were both immediately accretive to Neogen’s top and bottom lines. Neogen recently completed extensive renovations to its facilities in Lansing, Mich., to accommodate production of its new antibiotic testing products. The company continues to anticipate a key U.S. FDA approval for the domestic use of its advanced Beta Star dairy antibiotic testing product within its 2007 fiscal year.

Annual sales for Neogen’s Animal Safety Division increased 8% to $37,482,000. In addition to a record year for Neogen’s equine botulism vaccine and veterinary immune stimulant, sales of the company’s line of over-the-counter veterinary instruments offered in major farm and ranch retail stores increased 16% in FY 2006. Sales of forensic drug detection kits, TMB substrates and research test kits increased 15% compared to the prior year.

Acquisitions and Neogen’s sales efforts outside North America helped increase international sales to 29% of total company revenues, compared to 27% and 25% in the prior two fiscal years. Scotland-based Neogen Europe Ltd. continued its success in the European Union food safety testing market. Neogen Europe recorded an overall sales improvement of approximately 12%, with significant sales increases of Neogen’s mycotoxin, food allergen, and sanitation testing products.

Subsequent to the May 31 close of its 2006 fiscal year, Neogen generated approximately $12,237,000 in cash through an offering of 650,000 shares of common stock.

“Because the financial statements that we are reporting with this release offer a snapshot of our financial status as of May 31, our balance sheet shows that we have approximately $10 million of bank debt associated with our UCB and Centrus acquisitions,” said Richard Current, Neogen’s chief financial officer. “The proceeds from the stock offering fully retired all our bank debt and added to our cash balances. As of the date of this release, we have no long-term debt, and have full access to our $17.5 million bank line to pursue possible growth strategies.”

On June 16, Neogen’s Board of Directors elected Chief Operating Officer Lon Bohannon as the company’s president and chief operating officer. Bohannon immediately replaced James Herbert, who had served as Neogen’s president since its founding in 1982. Herbert has continued full-time responsibilities as chief executive officer, where his efforts will be focused on strategic growth and international expansion. Concurrently, Herbert was elected as Board chairman, replacing Jack Parnell, who will continue to serve on the Board.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company’s Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases, and sanitation concerns, and dehydrated culture media. Neogen’s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.


NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA

(In thousands, except for per share and percentages)

 

    

Quarter ended

May 31

   

Year ended

May 31

 
     2006     2005     2006     2005  
     (In thousands, except for per share)  

Revenue

  

Food Safety

   $ 10,595     $ 7,263     $ 34,951     $ 28,156  

Animal Safety

     9,220       8,745       37,482       34,600  
                                

Total revenue

     19,815       16,008       72,433       62,756  

Cost of sales

     9,662       7,962       35,427       32,153  
                                

Gross margin

     10,153       8,046       37,006       30,603  

Operating expenses

        

Sales & marketing

     4,430       3,497       15,799       13,484  

Administrative

     1,939       1,772       6,174       5,621  

Research & development

     649       596       2,988       2,729  
                                

Total operating expenses

     7,018       5,865       24,961       21,834  
                                

Operating income

     3,135       2,181       12,045       8,769  

Other income (expense)

     (132 )     (38 )     46       147  
                                

Income before income tax

     3,003       2,143       12,091       8,916  

Income tax

     1,046       698       4,150       3,000  
                                

Net income

   $ 1,957     $ 1,445     $ 7,941     $ 5,916  

Net income per diluted share

   $ 0.22     $ 0.17     $ 0.92     $ 0.70  

Other information:

        

Shares to calculate per share

     8,799       8,415       8,644       8,492  

Depreciation & amortization

     937       346       2,417       1,702  

Interest expense

     168       8       283       84  

Gross margin (% of sales)

     51.2 %     50.3 %     51.1 %     48.8 %

Operating income (% of sales)

     15.8 %     13.6 %     16.6 %     14.0 %

Revenue increase vs. FY 2005

     23.8 %       15.4 %  

Net income increase vs. FY 2005

     35.4 %       34.2 %  


NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

 

     31-May
2006
   31-May
2005
     (In thousands)

Assets

     

Current assets

     

Cash & securities

   $ 1,958    $ 1,972

Accounts receivable

     13,116      10,469

Inventories

     17,626      13,796

Other current assets

     3,269      2,142
             

Total current assets

     35,969      28,379

Property & equipment

     14,255      12,193

Goodwill & other assets

     37,766      23,312
             

Total assets

   $ 87,990    $ 63,884

Liabilities & Stockholders’ Equity

     

Current liabilities

   $ 10,017    $ 5,735

Long-term debt

     9,955      —  

Other long-term liabilities

     3,470      3,314

Equity

     64,548      54,835
             

Total liabilities & stockholders’ equity

   $ 87,990    $ 63,884

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s most recently filed Form 10-K.

###

-----END PRIVACY-ENHANCED MESSAGE-----